A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment

Journal of Theoretical Biology

Volumn 367, Issue , 2015, Pages 166-179

  Pienaar, Elsje ^a,b   Cilfone, Nicholas A ^a   Lin, Philana Ling ^c   Dartois, Véronique ^d   Mattila, Joshua T ^e   Butler, J Russell ^f   Flynn, JoAnne L ^e   Kirschner, Denise E ^b   Linderman, Jennifer J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f Florida   (United States)

Author keywords

Agent based model; Antibiotic gradients; Granuloma; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ISONIAZID; RIFAMPICIN; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ANTIBIOTICS; DISEASE TREATMENT; DRUG DEVELOPMENT; HOST; IMMUNITY; NUMERICAL MODEL; TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BAYESIAN LEARNING; CALIBRATION; CELL SUBPOPULATION; COMPUTER MODEL; COMPUTER PREDICTION; CONCENTRATION RESPONSE; DATA ANALYSIS SOFTWARE; DISEASE SIMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; LUNG GRANULOMA; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PHARMACODYNAMICS; PHARMACOKINETICS; SENSITIVITY ANALYSIS; SPATIOTEMPORAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TUBERCULOSIS; UNCERTAINTY; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GRANULOMA; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNITY; IMMUNOLOGY; MICROBIOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PRIMATE; TIME;

ANIMALIA; BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CALIBRATION; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOMA; HUMANS; IMMUNITY; ISONIAZID; MICE; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PRIMATES; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84919742532     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2014.11.021     Document Type: Article

References (81)

1. Barclay W.R., et al. Distribution and excretion of radioactive isoniazid in tuberculous patients. J. Am. Med. Assoc. 1953, 151(16):1384-1388.
2. Barry C.E., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009, 7(12):845-855.
3. Blumberg H.M., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 167(4):603-662.
4. Boshoff H.I., Barry C.E. Tuberculosis - metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 2005, 3(1):70-80.
5. Bouvier d'Yvoire M.Y., Maire P. Dosage regimens of antibacterials. Clin. Drug Investig. 1996, 11(4):229-239.
6. Budha N.R., et al. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis 2009, 89(5):378-385.
7. Capuano S.V., et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 2003, 71(10):5831-5844.
8. Cilfone N.A., et al. Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PloS One 2013, 8(7):e68680.
9. Cilfone N.A., Kirschner D.E., Linderman J.J. Strategies for efficient numerical implementation of hybrid multi-scale agent-based models to describe biological systems. Cell. Mol. Bioeng. 2014, http://dx.doi.org/10.1007/s12195-014-0363-6.
10. Cilfone, N.A., Ford, C.B., Marino, S., Mattila, J.T., Gideon, H.P., Flynn, J.L., Kirschner, D.E., Linderman, J.J., 2014b. Computational modeling predicts interleukin-10 control of lesion sterilization by balancing early host-immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection. J. Immun. http://dx.doi.org/10.4049/jimmunol.1400734.
11. Connolly L.E., Edelstein P.H., Ramakrishnan L. Why is long-term therapy required to cure tuberculosis?. PLoS Med. 2007, 4(3):e120.
12. Costa B. Spectral methods for partial differential equations. CUBO 2004, 6(4):1-32.
13. de Steenwinkel J.E., et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 2010, 65(12):2582-2589.
14. Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J. Infect. Dis. 2011, 204(12):1827-1829.
15. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 2014, 12(3):159-167.
16. Deb C., et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 2009, 4(6):e6077.
17. Domingos P., Pazzani M. On the optimality of the simple Bayesian classifier under zero-one loss. Mach. Learn. 1997, 29(2-3):103-130.
18. Egelund E.F., Barth A.B., Peloquin C.A. Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment. Curr. Pharm. Des. 2011, 17(27):2889-2899.
19. Emile J.F., et al. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. J. Pathol. 1997, 181(1):25-30.
20. Fallahi-Sichani M., et al. Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation. J. Immunol. 2011, 186(6):3472-3483.
21. Fallahi-Sichani M., et al. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J. Immunol. 2012, 188(7):3169-3178.
22. Flynn J.L., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2(6):561-572.
23. Forsgren A., Bellahsene A. Antibiotic accumulation in human polymorphonuclear leucocytes and lymphocytes. Scand. J. Infect. Dis. Suppl. 1985, 44:16-23.
24. Garton N.J., et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 2008, 5(4):e75.
25. Goutelle S., et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 2009, 53(7):2974-2981.
26. Goutelle S., et al. Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin. J. Theor. Biol. 2011, 282(1):80-92.
27. Griffiths G., et al. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat. Rev. Microbiol. 2010, 8(11):827-834.
28. Gumbo T., et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 2007, 51(7):2329-2336.
29. Hermsen R., Deris J.B., Hwa T. On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc. Natl. Acad. Sci. USA 2012, 109(27):10775-10780.
30. Iseman M.D. Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl. 2002, 36:87s-94s.
31. Jayaram R., et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 2003, 47(7):2118-2124.
32. Jayaram R., et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 2004, 48(8):2951-2957.
33. Jeena P.M., et al. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob. Agents Chemother. 2011, 55(2):539-545.
34. Jindani A., Dore C.J., Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 2003, 167(10):1348-1354.
35. Kaneko H., et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab. Investig. 1999, 79(4):379-386.
36. Kirschner D.E., et al. Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models. Wiley Interdiscip. Rev. Syst. Biol. Med. 2014, 6(4):289-309.
37. Kislitsyna N.A. Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients. Probl. Tuberk. 1985, (4):55-57.
38. Kislitsyna N.A., Kotova N.I. Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations. Probl. Tuberk. 1980, (8):63-65.
39. Kjellsson M.C., et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 2012, 56(1):446-457.
40. Kohavi, R., 1995. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Proceedings of the 14th International Joint Conference on Artificial Intelligence - Volume 2. Morgan Kaufmann Publishers Inc., Montreal, Quebec, Canada, pp. 1137-1143.
41. Lemmer Y., et al. A model of isoniazid treatment of tuberculosis. J. Theor. Biol. 2014, 363:367-373.
42. Lienhardt C., et al. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia. Int. J. Tuberc. Lung Dis. 1998, 2(9):712-718.
43. Lin P.L., et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 2006, 74(7):3790-3803.
44. Lin P.L., et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 2009, 77(10):4631-4642.
45. Lin P.L., et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl. Acad. Sci. USA 2012, 109(35):14188-14193.
46. Lin P.L., et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob. Agents Chemother. 2013, 57(9):4237-4244.
47. Lin P.L., et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 2014, 20(1):75-79.
48. Linderman J.J., Kirschner D.E. In silico models of M. tuberculosis infection provide a route to new therapies. Drug Discov. Today: Dis. Models, 2014, 10.1016/j.ddmod.2014.02.006.
49. Lipsitch M., Levin B.R. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 1997, 41(2):363-373.
50. Loos U., et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 1985, 63(23):1205-1211.
51. Lyons M.A., et al. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob. Agents Chemother. 2013, 57(4):1763-1771.
52. Mahapatra S., et al. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob. Agents Chemother. 2012, 56(1):28-35.
53. Marino S., et al. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput. Biol. 2007, 3(10):1909-1924.
54. Marino S., et al. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 2008, 254(1):178-196.
55. McFee R.B. Update - pathogens of concern. Dis. Mon. 2013, 59(12):437-438.
56. Mor N., et al. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 1995, 39(9):2073-2077.
57. Mugler D.H., Scott R.A. Fast fourier transform method for partial differential equations, case study: the 2-D diffusion equation. Comput. Math. Appl. 1988, 16(3):221-228.
58. Peloquin C. What is the 'right' dose of rifampin?. Int. J. Tuberc. Lung Dis. 2003, 7(1):3-5.
59. Peloquin C.A., et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 1997, 41(12):2670-2679.
60. Piccaro G., et al. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob. Agents Chemother. 2013, 57(3):1428-1433.
61. Prideaux B., et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 2011, 83(6):2112-2118.
62. Pruijn F.B., et al. Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust. J. Chem. 2008, 61(9):687-693.
63. Ray J.C., Flynn J.L., Kirschner D.E. Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J. Immunol. 2009, 182(6):3706-3717.
64. Regoes R.R., et al. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 2004, 48(10):3670-3676.
65. Reisfeld B., et al. A physiologically based pharmacokinetic model for capreomycin. Antimicrob. Agents Chemother. 2012, 56(2):926-934.
66. Ridley M.J., et al. Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. J. Pathol. 1983, 141(2):97-112.
67. Rish, I., 2001. An Empirical Study of the Naive Bayes Classifier.
68. Rivero-Lezcano O.M. Cytokines as immunomodulators in tuberculosis therapy. Recent Pat. Antiinfect. Drug Discov. 2008, 3(3):168-176.
69. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 2009, 8(10):2861-2871.
70. Segovia-Juarez J.L., Ganguli S., Kirschner D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J. Theor. Biol. 2004, 231(3):357-376.
71. Shandil R.K., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 2007, 51(2):576-582.
72. Srivastava S., et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 2011, 204(12):1951-1959.
73. Uhlin M., et al. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 2012, 205(Suppl. 2):S325-S334.
74. Via L.E., et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 2008, 76(6):2333-2340.
75. WHO, 2013. Global Tuberculosis Report.
76. Wallis R.S., et al. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013, 8(8):e71116.
77. Wilkins J.J., et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 2008, 52(6):2138-2148.
78. Wilkins J.J., et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br. J. Clin. Pharmacol. 2011, 72(1):51-62.
79. Zhang Q., et al. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science 2011, 333(6050):1764-1767.
80. Ziglam H.M., et al. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 2002, 50(6):1011-1015.
81. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12(5):388-404.